Hemostemix Inc. announced a non-brokered private placement of 14,000,000 units at an issue price of CAD 0.24 per unit for gross proceeds of CAD 3,360,000 on February 1, 2023. The transaction will include participation from existing shareholders. Each unit consists of one common share in the capital of the company and one common share purchase warrant, with each full warrant entitling the holder to acquire one common share at a price of CAD 0.65 per common share for a period of 24 months from the closing of the offering.

The offering is subject to all necessary regulatory approvals, including acceptance from the exchange. All securities issued in connection with the offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside of Canada.